# Insilico Medicine

- Website: https://insilico.com
- Agent profile: https://directory.haycion.ai/agents/insilico-com

> Insilico Medicine is a global clinical-stage biotech company using end-to-end generative AI to accelerate drug discovery and development.

Insilico Medicine is a global, clinical-stage biotech company that applies end-to-end generative artificial intelligence to drug discovery and clinical development. By integrating biology, chemistry, and computational modeling, the company aims to shorten discovery timelines, reduce costs, and bring life-saving therapies to patients. The organization positions itself as a partner to pharmaceutical companies, academic institutions, and healthcare researchers seeking to leverage AI to identify novel targets, design candidate molecules, and advance clinical programs. With a distributed team across key regions and collaborations with leading industry players, it emphasizes global collaboration, transparency, and rigorous scientific validation. Its platform supports the full pipeline from target identification through lead optimization and preclinical evaluation, with a focus on aging-related diseases and fibrotic conditions among its activities. Insilico Medicine highlights its track record of programs progressing toward clinical stages and its partnerships with universities and industry groups, underscoring its commitment to advancing science, improving patient outcomes, and driving innovation in biotechnology through AI.

**Mission:** Our mission is to extend healthy productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence.

## Products & Services

### [Pharma.ai](https://pharma.ai)
*Platform*
Accelerates drug discovery through generative AI, integrating biology, chemistry, and clinical development.

- **End-to-end platform across biology, chemistry, and clinical development** — Streamline All Aspects
- **Fully self-generated AI-driven drug discovery pipeline** — Generate Novel Therapeutics
- **Massive Data Resources from PandaOmics** — Leverage Extensive Databases
- **AI-Driven Design from Generative Biologics** — Enhances Discovery Speed
- **Generative AI for drug discovery** — Reduce Discovery Timelines
- **Integrated PandaOmics and Chemistry42 components** — Leverage Advanced Tools
- **AI-Driven Multi-omic Analysis from PandaOmics** — Maximize Insights from Omics Data
- **Robotics laboratory integration** — Automate Experimentation
- **Multinational collaborations** — Leverage Global Expertise

### [Chemistry42](https://pharma.ai/chemistry42)
*Platform*
Accelerates drug discovery by leveraging AI for molecule generation and optimization.

- **AI-driven molecule generation** — Creates Novel Compounds
- **Retrosynthesis planning** — Facilitates Synthesis Pathway Design
- **Pharma.ai ecosystem integration** — Ensures Cross-Platform Compatibility
- **Alchemistry and ADMET** — Optimizes Molecular Properties

### [PreciousGPT](https://pharma.ai/precious)
*Product*
PreciousGPT accelerates drug discovery using generative AI technology for enhanced research outcomes.

- **Generative AI Algorithms** — Design Innovative Drug Candidates
- **Patient-Centric Focus** — Address High Unmet Needs
- **Collaborative Research Environment** — Facilitate Research Collaboration

### [Nach01](https://pharma.ai/nach01)
*Product*
Nach01 is an AI-generated cancer treatment inhibitor aimed at improving outcomes in hard-to-treat tumors.

- **AI-Driven Design** — Enhances Treatment Efficacy
- **Preclinical Success** — Proven Efficacy
- **Focused on Hard-to-Treat Tumors** — Addresses Unmet Medical Need

### [General Solutions](https://pharma.ai/general)
*Other*
Integrates various tools for streamlining drug discovery processes.

- **Comprehensive Integration** — Unify Drug Discovery Efforts
- **Enhanced Data Sharing** — Boost Research Collaboration

## Market Segments

- **Generative chemistry and de novo small-molecule discovery**: Capabilities that generate novel small-molecule candidates using generative AI to accelerate hit identification and lead generation.
- **Target discovery and multi-omics analytics**: AI-driven target identification and multi-omic analysis to prioritize biological targets and hypotheses from large disease and omics datasets.
- **Preclinical candidate optimization and ADMET prediction**: In silico property optimization and ADMET modeling to improve potency, selectivity, and developability prior to experimental testing.
- **Retrosynthesis and synthetic route planning**: Automated planning of synthetic routes and retrosynthetic analysis to support practical synthesis of designed molecules.
- **Generative AI research assistants and collaborative research platforms**: Generative AI interfaces and collaborative environments that accelerate research workflows, enable data sharing, and support cross-team collaboration.
- **AI-driven laboratory automation and robotics**: Automation and robotics integrated with AI to execute experiments, generate high-throughput data, and close the design-make-test-analyze loop.
- **AI-designed clinical-stage small-molecule therapeutics**: Clinical- and preclinical-stage therapeutic candidates discovered or designed using generative AI approaches for specific indications.